Drug Type Monoclonal antibody |
Synonyms DR6(Boston Immune Technologies & Therapeutics) |
Target |
Action modulators |
Mechanism TNFRSF21 modulators(Tumor necrosis factor receptor superfamily member 21 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Discovery | United States | 01 Jul 2025 |






